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involving the axial skeleton and is included 
in the family of inflammatory spondylo-
arthropathies (SpAs). The clinical course 
of the disease is complicated by several 
extra-articular manifestations subdivided 
into those that are SpA-related, such as 
acute anterior uveitis, inflammatory bowel 
disease and psoriasis, and those that are 
non-SpA-related, such as lung and cardio-
vascular involvement [1]. 
Several studies reported an increased 
overall mortality in AS as much as 1.6–1.9 
times that of the general population, in addi-
tion to a higher mortality rate of 20–40% 
for circulatory or cardiovascular diseases 
[2]. A large population-based study, which 
included 21,473 AS patients and 86,606 
controls living in Ontario, Canada, showed 
that vascular mortality was significantly 
higher in AS patients compared to the 
general population. Moreover, there was a 
36% higher risk for vascular mortality when 
adjusted for baseline cardiovascular risk 
factors, hazard ratio (HR) 1.36, 95% con-
fidence interval (CI) 1.13–1.65 [3]. When 
stratified according to gender, this risk was 
particularly significant among male subjects 
(HR 1.46, 95%CI 1.13–1.87). Compared to 
controls, patients with AS had a 60% higher 
risk of cerebrovascular mortality (HR 1.60, 
95%CI 1.17–2.20) and a 35% higher risk 
for cardiovascular mortality (HR 1.35, 
95%CI 1.07–1.70) [3]. The data confirm an 
increased risk of cardiovascular morbidity 
and mortality, which can only partially be 
explained by the high prevalence of tradi-
tional cardiovascular risk factors among 
patients with AS, and are mainly due to the 
immuno-mediated inflammatory pattern of 
T he clinical course of ankylosing spon-dylitis (AS) is complicated by several 
extra-articular spondyloarthritis (SpA)-
related manifestations (such as acute ante-
rior uveitis, inflammatory bowel disease 
and psoriasis) and non-SpA-related mani-
festations (such as lung and cardiovascular). 
Cardiovascular involvement in AS is highly 
heterogeneous and may affect the pericar-
dium, endocardium, cardiac muscle and 
valves, conduction system, coronary arter-
ies, or large or small vessels of the systemic 
circulation, which may increase the risk 
of premature ischemic heart disease and 
stroke. The level and expression of cardio-
vascular involvement varies widely from the 
activity of the disease and the drugs used to 
treat the disease, which can aggravate or 
protect against cardiovascular disorders. 
The progress in imaging techniques makes 
it possible to identify atherosclerosis-related 
changes at their earliest stages. Cardiologists 
and rheumathologists should be fully aware 
of the increased cardiovascular risks of these 
patients in order to treat and prevent them. 
Ankylosing spondylitis (AS) is a chronic 
inflammatory disease predominantly 
the diseases themselves and the potentially 
unfavorable cardiovascular and metabolic 
effects caused by the corticosteroidal and 
non-corticosteroidal anti-inflammatory 
drugs used to treat them. In a meta-analysis, 
no differences were found in terms of blood 
pressure, glucose levels and atherogenic 
index (the ratio of total cholesterol/HDL 
cholesterol) between AS patients and a 
control group [4], although an increased 
relative risk of metabolic syndrome (clus-
ter of metabolic abnormalities including 
obesity, insulin resistance, glucose intoler-
ance, hypertension, and dyslipidemia) was 
found in AS patients, relative risk (RR) 2.13, 
95%CI 1.48–3.06 [4].
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are the first choice of therapy in 
treating AS [5]. Although NSAIDs lead to 
cardiovascular risks, data from AS stud-
ies suggest a favorable cardiovascular risk 
profile of long-term NSAID use in addition 
to reducing pain and improving mobility. 
Clearly individual risk assessments includ-
ing age and consideration of co-morbidities 
is required before making a decision on 
long-term NSAID use. Corticosteroid 
therapy is not recommendated for treating 
AS patients [6], but data from other studies 
and registries showed that these patients 
(particularly those with the peripheral 
form) are treated with these drugs despite 
their adverse effects [7].
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leukocyte antigen B27 (HLA-B27) positivity, 
and extra-spinal features such as peripheral 
arthritis, may predispose certain patients 
who are susceptible to aortic disease [10,11]. 
One of the well-known cardiac compli-
cations of AS is conduction system abnor-
malities. Chronic inflammation originating 
from the proximal aorta may extend into 
the membranous part of the interventricu-
lar septum and atrioventricular nodal area 
inducing several forms of arrhythmias and 
conduction blocks. When compared with 
the general population the most prevalent 
form of conduction blocks is atrioventricu-
lar, which is predominantly localized in the 
suprahisian region [12]. However, the sino-
atrial node dysfunction, Wolff–Parkinson–
White (WPW) syndrome, tachycardia, 
bradycardia, or interventricular conduction 
abnormalities have also been described 
[13]. The observed abnormalities seem to 
be more frequent among males, and HLA-
B27 patients seem to be more suseptible, 
but these abnormalities are also found in 
women and HLA-B27 patients who are 
negative for AS [14]. Clinical manifesta-
tions may range from asymptomatic to 
severe, requiring a pacemaker. 
With the use of echocardiography an 
increase of myocardial disease was found 
in AS. In particular, results showed that AS 
patients without cardiorespiratory symp-
toms, or known cardiac abnormalities, had 
diastolic left ventricular dysfunction, which 
is a precursor to heart failure. A possible 
explanation is that a systemic inflammation 
gradually damages the cardiomyocytes and 
causes increased collagen deposition in the 
heart. Clinical significance of asymptom-
atic left ventricular diastolic dysfunction 
in AS is not yet entirely clear, but it has 
been reported in 10–50% of AS patients 
according to different studies [15]. Recently, 
Atzeni and colleagues [16] showed, using 
two-dimensional speckle tracking echocar-
diography (2D-STE) to assess end-systolic 
left ventricular longitudinal strain (ε), that 
AS patients with still negative traditional 
ecocardiography parameters had impaired 
STE-measured myocardial, thus suggesting 
a myocardial alteration [16]. 
Finally, considering that the increased 
prevalence, although still unknown, of this 
complication that can lead to heart failure, 
we suggest developing prevention and treat-
ment strategies for these patients. 
RECENT CARDIOVASCULAR 
COMPLICATIONS 
Recently, imaging techniques have made it 
possible to identify atherosclerosis-related 
changes at their earliest stages [17] [Figure 1, 
Figure 2]. Several invasive and non-invasive 
techniques are used to identify early arte-
rial wall alterations. Intima-media thickness 
(IMT) of common carotid arteries (CCA) 
and assessment of flow-mediated dilatation 
(FMD) by ultrasound are the most widely 
used non-invasive methods. IMT of CCA 
is a reproducible marker of generalized ath-
erosclerosis that allows for the evaluation of 
the earliest structural changes in the arte-
rial wall. FMD is used to detect endothelial 
est defined cardiovascular manifestations 
of AS. AS can affect various segments of 
the aorta, particularly the ascending aorta 
[8]. Histologically, aortitis is defined by the 
presence of inflammatory infiltrates in the 
medial and/or intimal layers of the tissue. 
Inflammation may cause dilatation and 
reduced arterial elasticity. Dilatation of the 
proximal aorta along with the thickened 
cusps may cause valvular regurgitation in 
up to 20% of the patients [8]. Before the 
advent of echocardiography the estimated 
prevalence of aortic valve was approxi-
mately 1–10% [9]. Later studies using 
echocardiography provided a prevalence 
around 18–20% [10,11]. The explantion for 
aortitis is that the inflammation caused by 
AS is often located in the entheses, which 
are the attachments of tendons, ligaments, 
or joint capsules to bone or cartilage [1]. 
Entheses are regions of “wear and tear” 
where micro damage frequently occurs, 
followed by inflammation and new bone 
formation as a reparative. The attachment 
of the aortic cusps in the heart, with their 
central tendon-like fibrous core, shows 
some resemblance to enthesis [1]. Like ten-
don insertions, the attachment points of the 
aortic cusps are also regions that are subject 
to mechanical stress followed by inflamma-
tion and repetative mechanisms.
In general, many of the cases are sub-
clinical but some of the patients may require 
surgical intervention. Longer disease dura-
tion and aging are likely to increase the aor-
tic lesions. Combination of several factors, 
including higher disease activity, human 
Figure 1. Chronic total occlusion of left anterior descending artery
CBA
EDITORIALS
508 
,0$-ǯ92/19ǯ$8*8672017
for sub-clinical atherosclerosis and target 
plasma lipid levels. A recent post hoc anal-
ysis of two statin trials has found that the 
reduction to cardiovascular risk in patients 
with autoimmune diseases is comparable 
to that observed in patients with other 
conditions [20], but these findings need 
to be validated by controlled clinical tri-
als to demonstrate unequivocally whether 
aggressively treating cardiovascular risk 
factors with the same targets as those rec-
ommended for patients with conditions 
of equivalent risk is also capable of reduc-
ing the number of events in patients with 
chronic inflammatory diseases.
CONCLUSIONS
In conclusion, it is particularly important 
that cardiologists and rheumathologists are 
fully aware of the increased cardiovascular 
risk of patients with AS, the precocity of the 
onset of cardiac involvement, the need for 
aggressive treatment of traditional risk fac-
tors, and the favorable or unfavorable role 
of the medications used to treat systemic 
inflammatory diseases.
Finally, considering the increased car-
diovascular disease risk, we suggest devel-
oping prevention and treatment strategies 
for AS patients as well as guidelines and a 
standardized approach for cardiovascular 
examination and laboratory workup in 
routine clinical care of AS patients.
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cerning the need for screening asymptom-
atic patients for sub-clinical atherosclerosis 
or which target plasma lipid levels can be 
considered satisfactory in patients with AS. 
Furthermore, although it is already known 
that corticosteroids have undesirable effects 
on cardiovascular risk factors, the effects of 
methotrexate and sulphasalazine are favor-
able. Further evidence is needed concern-
ing the impact of other drugs (particularly 
biological drugs) on the onset of cardio-
vascular co-morbidities. Although there is 
some research that shows a positive impact 
on vascular function, available data do not 
support a direct beneficial effect of anti-
tumor necrosis factor (TNF) treatments on 
cardiovascular disease [16,18]. Based on the 
known role of inflammation in the patho-
genesis of the atherosclerotic process, it can 
be extrapolated that systemic inflammatory 
disease has many and various effects on 
overall cardiovascular risk. A more ath-
erogenous lipid profile, forced reduction in 
physical activity, activation and expression 
of cytokines and other molecules involved 
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and cardiovascular and metabolic effects 
of the most widely prescribed medica-
tions can all synergistically worsen the risk 
of cardiovascular diseases. It is therefore 
possible that controlling inflammation 
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early rehabilitation, optimally by control-
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metabolic profiles, can reduce the effects of 
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directed screening procedures can detect 
cardiovascular manifestations earlier. 
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between AS and cardiovascular risk has 
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published guidelines of the European 
Society of Cardiology, which has a specific 
section dedicated to preventing cardio-
vascular disease  in patients with systemic 
autoimmune inflammatory diseases [19]. 
However, some important aspects of the 
clinical management of cardiovascular risk 
in patients with AS are still uncertain and 
not considered in the guidelines, including 
the screening of asymptomatic patients 
dysfunction, which precedes morphologi-
cal changes and is believed to be the initial 
step in the development of atherosclerosis. 
Impaired endothelial function has been 
reported in various studies in AS. In one 
meta-analyis Mathieu et al. [4] analyzed six 
studies and reported an increased IMT in 
the AS group. Arida and co-authors [17] 
showed that carotid IMT, but not plaque 
burden, was significantly increased in AS 
compared to controls. AS without clinically 
evident cardiovascular disease has a high 
prevalence of subclinical vascular involve-
ment. It is still not clear what physiopatho-
logical mechanisms underlie the relation-
ship between systemic inflammation and 
increased cardiovascular risk as none of the 
many hypotheses that have been proposed 
has yet been fully confirmed. 
From the point of view of everyday clin-
ical practice, there is still uncertainty con-
Figure 2. Previous anterior acute myocardial 
infarct
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Preeclampsia impairs fetal growth and can damage maternal 
organs. Reactive oxygen species (ROS) have been proposed 
to increase the risk of preeclampsia by blocking blood vessel 
formation (angiogenesis) in the placenta. However, using 
a mouse model of preeclampsia, Nezu et al. found that 
decreasing ROS levels led to reduced placental angiogenesis, 
fetal growth, and maternal survival. In contrast, increased 
ROS levels resulted in greater placental angiogenesis and 
improved fetal and maternal outcomes. These results help to 
explain why antioxidants have been ineffective at preventing 
preeclampsia in clinical trials.
Sci Signal 2017; 10: eaam5711
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Why antioxidants do not prevent preeclampsia
How immunological T cells scan target cells for ligands is 
poorly understood. Cai and co-authors examined microvillar 
dynamics in living T cells in three dimensions and in real 
time. The T cells palpated all spots on a surface within about 
1 minute through rapid movements of their microvilli. The 
time it took to scan the surface matched the movement rate 
of cells through tissues. These contacts took place in the 
absence of T cell receptor recognition and were stabilized 
independently of signaling or the cytoskeleton. Instead, 
stabilization depended on ligand afﬁnity. The ﬁndings explain 
why many of the previously described components of the 
immunological synapse and T cell receptor signaling reside on 
three-dimensional microvillar-derived projections.
Science 2017; 356: 598
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Search and capture in space and time
“From things that have happened and from things as they exist and from all things that you 
know and all those you cannot know, you make something through your invention that is not a 
representation but a whole new thing truer than anything true and alive, and you make it alive, 
and if you make it well enough, you give it immortality”
Ernest Hemingway (1899–1961) American novelist, short story writer, and journalist
